Pirruccello, James P. http://orcid.org/0000-0001-6088-4037
Bick, Alexander
Wang, Minxian http://orcid.org/0000-0002-3753-508X
Chaffin, Mark http://orcid.org/0000-0002-1234-5562
Friedman, Samuel
Yao, Jie
Guo, Xiuqing
Venkatesh, Bharath Ambale
Taylor, Kent D.
Post, Wendy S.
Rich, Stephen http://orcid.org/0000-0003-3872-7793
Lima, Joao A. C. http://orcid.org/0000-0001-8756-6995
Rotter, Jerome I.
Philippakis, Anthony
Lubitz, Steven A.
Ellinor, Patrick T.
Khera, Amit V.
Kathiresan, Sekar http://orcid.org/0000-0002-6724-032X
Aragam, Krishna G.
Funding for this research was provided by:
John S LaDue Memorial Fellowship for Cardiovascular Research
Foundation for the National Institutes of Health (1R01HL139731, R01HL128914, K24HL105780, HL127564)
American Heart Association (18SFRN34250007, 18SFRN34110082, 17IFUNP33840012)
Fondation Leducq (14CVD01)
Article History
Received: 30 July 2019
Accepted: 18 March 2020
First Online: 7 May 2020
Competing interests
: J.P.P. and A.B. have minor consulting roles with Maze Therapeutics. A.P. is a Venture Partner at GV, a venture capital group within Alphabet. In that capacity, he makes investments in companies in both the life sciences and data sciences, many of which are cardiovascular in focus. S.A.L. receives sponsored research support from Bristol Myers Squibb/Pfizer, Bayer AG, and Boehringer Ingelheim, and has consulted for Bristol Myers Squibb/Pfizer and Bayer AG. P.T.E. is supported by a grant from Bayer AG to the Broad Institute focused on the genetics and therapeutics of cardiovascular diseases, and has served on advisory boards or consulted for Bayer AG, Quest Diagnostics, and Novartis. S.K. is an employee of Verve Therapeutics, and holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics. He is a member of the scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; he has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, and Medscape; he reports patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). The remaining authors declare no competing interests.